Latest news with #Maravai
Yahoo
28-07-2025
- Business
- Yahoo
Maravai LifeSciences To Host Earnings Conference Call on Monday, August 11, 2025
SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2025 financial and operating results after the market close on Monday, August 11, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 267-6316 or (203) 518-9783 and reference Maravai LifeSciences, Conference ID MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at About Maravai Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. CONTACT: Contact Information: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-06-2025
- Business
- Yahoo
Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 26, William Blair reaffirmed its 'Market Perform' rating for Maravai stock. The key factor influencing this move is the leadership changes at Maravai. A scientist performing a blood test on a patient using life sciences tools & services. Maravai has undergone a complete leadership overhaul since December last year. In December 2024, the company brought in Andy Eckert as the new independent Chairman of the Board. Later, Maravai installed Bernd Brust as CEO, replacing Trey Martin. Then, on June 25, a new press release indicated that Rajesh 'Raj' Asarpota would assume the position of Executive Vice President and Chief Financial Officer, effective June 30. According to William Blair, Brust and Asarpota are joining Maravai's top-level management when the company is undergoing 'a challenging operational transition period.' The analysts noted that the company 'faces approximately $66 million in headwinds in 2025 from declining COVID-related revenues.' As such, the analysts are optimistic that the fresh hands at Maravai's helm will inject more momentum into the transition. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is a life sciences company. It provides specialized products that support the development of vaccines, drug therapies, diagnostics, and cell and gene therapies. Its operations span two segments: Nucleic Acid Production and Biologics Safety Testing. While we acknowledge the potential of MRVI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None.
Yahoo
29-06-2025
- Business
- Yahoo
Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 26, William Blair reaffirmed its 'Market Perform' rating for Maravai stock. The key factor influencing this move is the leadership changes at Maravai. A scientist performing a blood test on a patient using life sciences tools & services. Maravai has undergone a complete leadership overhaul since December last year. In December 2024, the company brought in Andy Eckert as the new independent Chairman of the Board. Later, Maravai installed Bernd Brust as CEO, replacing Trey Martin. Then, on June 25, a new press release indicated that Rajesh 'Raj' Asarpota would assume the position of Executive Vice President and Chief Financial Officer, effective June 30. According to William Blair, Brust and Asarpota are joining Maravai's top-level management when the company is undergoing 'a challenging operational transition period.' The analysts noted that the company 'faces approximately $66 million in headwinds in 2025 from declining COVID-related revenues.' As such, the analysts are optimistic that the fresh hands at Maravai's helm will inject more momentum into the transition. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is a life sciences company. It provides specialized products that support the development of vaccines, drug therapies, diagnostics, and cell and gene therapies. Its operations span two segments: Nucleic Acid Production and Biologics Safety Testing. While we acknowledge the potential of MRVI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of 'Maravai LifeSciencesReleases 2024 Sustainability Report'. The corrected title is 'Maravai LifeSciences Releases 2024 Sustainability Report'. Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2024 Sustainability Report, available on the Company's Sustainability webpage ( The new report highlights progress during calendar year 2024 across Maravai's four priority areas – Product Innovation, Our People, Governance, and Sustainable Growth – and underscores the Company's commitment to sustainable value creation. 'By embedding sustainability into every facet of our operations—from employee engagement to GMP scaleup — we foster innovation, strengthen our business resilience, and create long-term value for all stakeholders,' said Trey Martin, Chief Executive Officer. 'Our 2024 achievements position Maravai to remain our customers' first choice as they advance their programs in next-generation therapeutics and diagnostics.' Key highlights from the 2024 report include: Product Innovation Launched 49 new products across portfolio brands, including CleanCap® M6 analog now available at GMP quality Completed state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold Established RNA Innovation Center in collaboration with Johns Hopkins University Added to our GMP manufacturing expertise and have now manufactured over 130 GMP batches for mRNA Our People Achieved 95% participation rate in our annual employee engagement survey, receiving over 2,600 comments Expanded WE (We are Empowered) Employee Resource Group to facilitate advocacy, mentorship, and outreach across the organization Implemented new career framework creating transparent progression paths for all employees Continued our Impact Day program throughout 2024, with employees contributing approximately 800 volunteer hours Governance Appointed healthcare industry veteran R. Andrew Eckert as independent Chairman of the Board Adopted formal, publicly available Human Rights Policy 100% of standing Board Committees chaired by independent members Strengthened intellectual property position with additional CleanCap® patents in China and Canada Sustainable Growth Enhanced greenhouse gas emissions data collection and expanded Scope 3 emissions reporting Leland, North Carolina facility's solar panels generated over 180,000 kWh, offsetting approximately 20% of facility's energy use San Diego EV charging stations helped save over 19,000 gallons of gasoline Advanced planning for lab plastics recycling program and single-use plastic phase-out The 2024 report was prepared in reference to the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB) and Greenhouse Gas Protocol frameworks and maps selected disclosures to relevant U.N. Sustainable Development Goals (SDGs). About Maravai Maravai LifeSciences is an innovative lifesciences company that provides critical products to enable the development of breakthrough therapeutics, vaccines, cell and gene therapies and diagnostics. Through its TriLink BioTechnologies, Glen Research, Alphazyme and Cygnus Technologies brands, Maravai delivers complex nucleic acid chemistries, differentiated mRNA and enzyme solutions, and gold standard biologics safety tests to a global customer base spanning large pharmaceutical companies, emerging biotechs and leading academic institutions. Forward Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements related to future product offerings, facility capabilities, and sustainability initiatives. Forward-looking statements are neither historical facts nor assurances of future performance and are subject to risks and uncertainties that could cause actual results to differ materially. A detailed discussion of these risks is included in Maravai's most recent Annual Report on Form 10K and subsequent filings with the U.S. Securities and Exchange Commission. Maravai undertakes no obligation to update forward-looking statements except as required by law. CONTACT: Contact Information: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@
Yahoo
21-05-2025
- Business
- Yahoo
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of 'Maravai LifeSciencesReleases 2024 Sustainability Report'. The corrected title is 'Maravai LifeSciences Releases 2024 Sustainability Report'. Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2024 Sustainability Report, available on the Company's Sustainability webpage ( The new report highlights progress during calendar year 2024 across Maravai's four priority areas – Product Innovation, Our People, Governance, and Sustainable Growth – and underscores the Company's commitment to sustainable value creation. 'By embedding sustainability into every facet of our operations—from employee engagement to GMP scaleup — we foster innovation, strengthen our business resilience, and create long-term value for all stakeholders,' said Trey Martin, Chief Executive Officer. 'Our 2024 achievements position Maravai to remain our customers' first choice as they advance their programs in next-generation therapeutics and diagnostics.' Key highlights from the 2024 report include: Product Innovation Launched 49 new products across portfolio brands, including CleanCap® M6 analog now available at GMP quality Completed state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold Established RNA Innovation Center in collaboration with Johns Hopkins University Added to our GMP manufacturing expertise and have now manufactured over 130 GMP batches for mRNA Our People Achieved 95% participation rate in our annual employee engagement survey, receiving over 2,600 comments Expanded WE (We are Empowered) Employee Resource Group to facilitate advocacy, mentorship, and outreach across the organization Implemented new career framework creating transparent progression paths for all employees Continued our Impact Day program throughout 2024, with employees contributing approximately 800 volunteer hours Governance Appointed healthcare industry veteran R. Andrew Eckert as independent Chairman of the Board Adopted formal, publicly available Human Rights Policy 100% of standing Board Committees chaired by independent members Strengthened intellectual property position with additional CleanCap® patents in China and Canada Sustainable Growth Enhanced greenhouse gas emissions data collection and expanded Scope 3 emissions reporting Leland, North Carolina facility's solar panels generated over 180,000 kWh, offsetting approximately 20% of facility's energy use San Diego EV charging stations helped save over 19,000 gallons of gasoline Advanced planning for lab plastics recycling program and single-use plastic phase-out The 2024 report was prepared in reference to the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB) and Greenhouse Gas Protocol frameworks and maps selected disclosures to relevant U.N. Sustainable Development Goals (SDGs). About Maravai Maravai LifeSciences is an innovative lifesciences company that provides critical products to enable the development of breakthrough therapeutics, vaccines, cell and gene therapies and diagnostics. Through its TriLink BioTechnologies, Glen Research, Alphazyme and Cygnus Technologies brands, Maravai delivers complex nucleic acid chemistries, differentiated mRNA and enzyme solutions, and gold standard biologics safety tests to a global customer base spanning large pharmaceutical companies, emerging biotechs and leading academic institutions. Forward Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements related to future product offerings, facility capabilities, and sustainability initiatives. Forward-looking statements are neither historical facts nor assurances of future performance and are subject to risks and uncertainties that could cause actual results to differ materially. A detailed discussion of these risks is included in Maravai's most recent Annual Report on Form 10K and subsequent filings with the U.S. Securities and Exchange Commission. Maravai undertakes no obligation to update forward-looking statements except as required by law. CONTACT: Contact Information: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
